USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C] QUINAZOLINES FOR TREATING LYMPHOMAS

• 收藏
• 分享

专利权人:

BAYER PHARMA AKTIENGESELLSCHAFT

发明人:

WENGER ANTJE MARGRET,PAUL JULIANE,HAIKE KATJA

申请号：

AP2015008750

公开号：

AP2015008750A0

申请日:

2014.04.04

申请国别(地区):

AP

年份:

2015

代理人:

摘要：

Described herein arc methods of treating non-Hodgkin's lymphoma (NHL), wherein the non-Hodgkin's lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL)； follicular lymphoma (FL)； chronic lymphocytic leukemia (CLL)； marginal zone lymphoma (MZL)； diffuse large B-cell lymphoma (DLBCL)； mantle cell lymphoma (MCL)； transformed lymphoma (TL)； and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/